| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 冠昊生物科技股份有限公司（股票代码：300238）是一家立足再生医学产业，拓展生命健康相关领域，嫁接全球高端技术资源和成果的高新技术企业，持续在生物材料、细胞干细胞、药业、以及先进医疗技术、产品业务领域布局，核心业务形成“3+1”格局，即材料、细胞、药业三大业务板块和一个科技孵化平台。 在再生材料领域，经过十几年的发展，公司已经搭建的动物源性生物材料技术平台是具备竞争能力的医药技术平台。凭借在诱导再生功能的新型生物材料及其产品研发领域的研发实力，公司先后承担着二十多项国家和地方的科技攻关项目，由国家发展与改革委员会立项的“再生型医用植入器械国家工程实验室”和“再生型生物膜高技术产业化示范工程”先后落户冠昊生物。目前公司拥有国内外专利百余项，已上市的自主研发产品有生物型硬脑(脊)膜补片、B型硬脑膜补片、胸普外科修补膜(B/P)、无菌生物护创膜、艾瑞欧乳房补片、优得清脱细胞角膜植片；以及珠海祥乐代理的人工晶体产品，可广泛应用于神经外科、胸普外科、眼科、皮肤科、骨科、整形美容科等。 在细胞\干细胞领域，2013年公司与北京大学邓宏魁教授团队合作，建立北昊干细胞与再生医学研究院，持续开展了生物型人工肝细胞治疗技术研究。目前公司陆续开展自体软骨组织细胞移植技术、免疫细胞存储技术，干细胞储存与转化应用技术等研究与服务。 在药业领域，公司控股的广东中昊药业有限公司和北京文丰天济医药科技有限公司持有1类新药本维莫德大中华区的知识产权。本维莫德最初发现于一种天然微生物代谢产物中分离出来的非激素类小分子化合物。该药物可以用于治疗多种自身免疫性疾病，如银屑病（俗称“牛皮癣”），被国家科技部列为“十二五”、国家“重大新药创制”科技重大专项成果。2019年5月，1类创新药本维莫德乳膏通过国家药品监督局优先审批程序批准上市，7月获得广东省药品监督管理局颁发的《药品GMP证书》，该产品用于局部治疗成人轻至中度稳定性寻常型银屑病。 在科技孵化板块，冠昊科技园开创“上市公司+孵化器+产业基金”的专业创新孵化模式，致力打造国内专业的产融互动生命健康创新创业深孵化平台，并提供创业项目的整体解决方案和产业化转化的打包服务。2017年12月，冠昊科技园通过国家科技企业孵化器认定。 | ||||||||||||||||||||||||
| Main Business | 再生医学材料及再生型医用植入器械研发、生产及销售。 | ||||||||||||||||||||||||
| Legal Representative | 张永明 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 徐庆荣 | ||||||||||||||||||||||||
| Solicitors | 国浩律师（广州）事务所 | ||||||||||||||||||||||||
| Auditors | 立信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 020-32052295 | ||||||||||||||||||||||||
| Fax No | 020-32211255 | ||||||||||||||||||||||||
| Website | www.guanhaobio.com | ||||||||||||||||||||||||
| ir@guanhaobio.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 06/07/2011 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.120 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 1.963 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 2.988B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |